Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Multiple Sclerosis

  Free Subscription


20.03.2017

1 Arch Phys Med Rehabil
1 BMC Neurol
1 Hum Immunol
1 Int J Neurosci
4 J Neuroimmunol
1 J Neurol Neurosurg Psychiatry
10 Mult Scler
2 Nat Rev Neurol
1 Nervenarzt
1 Neurology
1 PLoS One
1 Rev Neurol (Paris)


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Arch Phys Med Rehabil

  1. EL-GOHARY M, Peterson D, Gera G, Horak FB, et al
    Validity of the instrumented push and release test to quantify postural responses in persons with multiple sclerosis.
    Arch Phys Med Rehabil. 2017 Mar 6. pii: S0003-9993(17)30137.
    PubMed     Text format     Abstract available


    BMC Neurol

  2. VAN DER MAAS NA
    Patient-reported questionnaires in MS rehabilitation: responsiveness and minimal important difference of the multiple sclerosis questionnaire for physiotherapists (MSQPT).
    BMC Neurol. 2017;17:50.
    PubMed     Text format     Abstract available


    Hum Immunol

  3. PANKRATZ S, Ruck T, Meuth SG, Wiendl H, et al
    CD4(+)HLA-G(+) regulatory T cells: Molecular signature and pathophysiological relevance.
    Hum Immunol. 2016;77:727-33.
    PubMed     Text format     Abstract available


    Int J Neurosci

  4. GAO C, Wu L, Chen X, Long Y, et al
    Hypothalamic abnormality in patients with inflammatory demyelinating disorders.
    Int J Neurosci. 2016;126:1036-43.
    PubMed     Text format     Abstract available


    J Neuroimmunol

  5. MASUDA H, Mori M, Uchida T, Uzawa A, et al
    Soluble CD40 ligand contributes to blood-brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2017;305:102-107.
    PubMed     Text format     Abstract available

  6. BUTTARI F, Zagaglia S, Marciano L, Albanese M, et al
    TRPV1 polymorphisms and risk of interferon beta-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2017;305:172-174.
    PubMed     Text format     Abstract available

  7. JACOB S, Al-Kandari A, Alroughani R, Al-Temaimi R, et al
    Assessment of plasma biomarkers for their association with Multiple Sclerosis progression.
    J Neuroimmunol. 2017;305:5-8.
    PubMed     Text format     Abstract available

  8. MUTO M, Mori M, Liu J, Uzawa A, et al
    Serum soluble Talin-1 levels are elevated in patients with multiple sclerosis, reflecting its disease activity.
    J Neuroimmunol. 2017;305:131-134.
    PubMed     Text format     Abstract available


    J Neurol Neurosurg Psychiatry

  9. MURPHY R, O'Donoghue S, Counihan T, McDonald C, et al
    Neuropsychiatric syndromes of multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Mar 11. pii: jnnp-2016-315367.
    PubMed     Text format     Abstract available


    Mult Scler

  10. CLERICO M, De Mercanti S, Artusi CA, Durelli L, et al
    Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.
    Mult Scler. 2017 Feb 1:1352458516688350. doi: 10.1177/1352458516688350.
    PubMed     Text format     Abstract available

  11. ROCCA MA, Valsasina P, Leavitt VM, Rodegher M, et al
    Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment.
    Mult Scler. 2017 Mar 1:1352458517699875. doi: 10.1177/1352458517699875.
    PubMed     Text format     Abstract available

  12. SHEIKH-TAHA M, Corman LC
    Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517694431. doi: 10.1177/1352458517694431.
    PubMed     Text format     Abstract available

  13. LEURS CE, Podlesniy P, Trullas R, Balk L, et al
    Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment.
    Mult Scler. 2017 Mar 1:1352458517699874. doi: 10.1177/1352458517699874.
    PubMed     Text format     Abstract available

  14. KALSON-RAY S, Edan G, Leray E
    An excessive risk of suicide may no longer be a reality for multiple sclerosis patients.
    Mult Scler. 2017 Mar 1:1352458517699873. doi: 10.1177/1352458517699873.
    PubMed     Text format     Abstract available

  15. RIO J, Rovira A, Tintore M, Otero-Romero S, et al
    Disability progression markers over 6-12 years in interferon-beta-treated multiple sclerosis patients.
    Mult Scler. 2017 Mar 1:1352458517698052. doi: 10.1177/1352458517698052.
    PubMed     Text format     Abstract available

  16. MARRIE RA
    What is the risk of suicide in multiple sclerosis?
    Mult Scler. 2017 Mar 1:1352458517699992. doi: 10.1177/1352458517699992.
    PubMed     Text format    

  17. CORTESE M, Riise T, Bjornevik K, Myhr KM, et al
    Body size and physical exercise, and the risk of multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517699289. doi: 10.1177/1352458517699289.
    PubMed     Text format     Abstract available

  18. RANGANATHAN U, Kaunzner U, Foster S, Vartanian T, et al
    Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517699876. doi: 10.1177/1352458517699876.
    PubMed     Text format     Abstract available

  19. COETZEE T, Thompson A
    When are we going to take modifiable risk factors more seriously in multiple sclerosis?
    Mult Scler. 2017;23:494-495.
    PubMed     Text format    


    Nat Rev Neurol

  20. MARRIE RA
    Comorbidity in multiple sclerosis: implications for patient care.
    Nat Rev Neurol. 2017 Mar 17. doi: 10.1038/nrneurol.2017.
    PubMed     Text format     Abstract available

  21. FYFE I
    Multiple sclerosis: Stem cell treatment suppresses multiple sclerosis in the long term.
    Nat Rev Neurol. 2017 Mar 10. doi: 10.1038/nrneurol.2017.
    PubMed     Text format    


    Nervenarzt

  22. DIEBOLD M, Kappos L, Derfuss T
    [Cell depletion and myoablation for neuroimmunological diseases].
    Nervenarzt. 2016;87:814-20.
    PubMed     Text format     Abstract available


    Neurology

  23. MARRIE RA, Salter A, Tyry T, Cutter GR, et al
    High hypothetical interest in physician-assisted death in multiple sclerosis.
    Neurology. 2017 Mar 15. pii: 10.1212/WNL.0000000000003831.
    PubMed     Text format     Abstract available


    PLoS One

  24. MULS N, Nasr Z, Dang HA, Sindic C, et al
    IL-22, GM-CSF and IL-17 in peripheral CD4+ T cell subpopulations during multiple sclerosis relapses and remission. Impact of corticosteroid therapy.
    PLoS One. 2017;12:e0173780.
    PubMed     Text format     Abstract available


    Rev Neurol (Paris)

  25. WILLEMAN T, Casez O, Faure P
    Biotin in multiple sclerosis and false biological hyperthyroidism: Mind the interference.
    Rev Neurol (Paris). 2017 Mar 14. pii: S0035-3787(16)30283.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: